IL7-IL15-iMSCs

IL7-IL15-iMSCs are an engineered cell-based biologic therapy consisting of mesenchymal stromal cells (MSCs) derived from induced pluripotent stem cells (iPSCs) that have been stably modified to express interleukin-7 (IL-7) and interleukin-15 (IL-15). These cells are generated by reprogramming adult dermal fibroblasts into iPSCs using a synthetic, non-integrating mRNA transfection system, followed by genetic modification and differentiation into the mesodermal lineage. Designed to overcome the limitations of primary bone marrow-derived MSCs, such as finite proliferative lifespan and donor variability, IL7-IL15-iMSCs function as an immunologically active platform that homes to the tumor microenvironment (TME). Once localized, they secrete supraphysiologic levels of IL-7 and IL-15, converting the immunosuppressive TME into an immune-activated state by promoting the infiltration and activation of T cells, NK cells, and tumoricidal M1-type macrophages while reducing regulatory T cells. The therapy is currently being developed for the treatment of solid tumors, including ovarian cancer and triple-negative breast cancer.

Other names

Engineered IL7/IL15 secreting iPSC-derived mesenchymal stromal cellsinterleukin-7 + interleukin-15 + induced mesenchymal stromal cells